NCT01424982 - Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2011

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveUntreated Adult Acute Lymphoblastic Leukemia

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Doxorubicin

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Methotrexate

Given IV

DRUG

Ponatinib

Given PO

DRUG

Ponatinib Hydrochloride

Given PO

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER